Adjusted operating margin fell 210 basis points to 25.7% as Zimmer Biomet continued investing in its U.S. sales channel. Zimmer Biomet repurchased $500 million of stock in the first half, including $250 million in the second quarter. Zimmer Biomet raised adjusted EPS guidance to $8.47 to $8.59, from $8.40 to $8.55. Zimmer Biomet expects to complete the transformation by the end of 2027. About Zimmer Biomet (NYSE:ZBH)Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare.